Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GGD GoGold Resources	C$2.23 -2.6%	C$2.16	C$1.04 ▼ C$2.41	C$518.91M	1.5	748,357 shs	215,908 shs
ITR Integra Resources	C$2.30 -0.9%	C$2.13	C$1.12 ▼ C$2.68	C$271.83M	1.37	414,570 shs	352,987 shs
NSR Neustar, Inc. Neustar, Inc. Cla	$7.76	$0.00	$21.10 ▼ $34.40	$477.94M	N/A	13,059 shs	N/A
SLS SELLAS Life Sciences Group	$1.55	$1.77	$0.77 ▼ $2.27	$163.21M	2.26	1.84 million shs	1.46 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GGD GoGold Resources	-2.62%	0.00%	-2.19%	+31.18%	+76.98%
ITR Integra Resources	-0.86%	+4.55%	+14.43%	+11.65%	+98.28%
NSR Neustar, Inc. Neustar, Inc. Cla	0.00%	0.00%	0.00%	0.00%	0.00%
SLS SELLAS Life Sciences Group	+0.32%	-3.13%	-18.42%	-4.91%	+29.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GGD GoGold Resources	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITR Integra Resources	2.5117 of 5 stars	3.5	0.0	0.0	0.0	3.2	2.5	0.0
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	2.8757 of 5 stars	3.5	2.0	0.0	0.0	3.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GGD GoGold Resources	0.00	N/A	N/A	N/A
ITR Integra Resources	3.00	Buy	C$4.31	87.50% Upside
NSR Neustar, Inc. Neustar, Inc. Cla	0.00	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	351.61% Upside

Current Analyst Ratings Breakdown

Latest ITR, SLS, NSR, and GGD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GGD GoGold Resources	C$35.15M	14.76	C$0.30 per share	7.52	C$1.18 per share	1.89
ITR Integra Resources	N/A	N/A	C$0.67 per share	3.41	C$0.45 per share	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$27.15M	17.60	$0.19 per share	41.83	$4.72 per share	1.64
SLS SELLAS Life Sciences Group	$1M	163.22	N/A	N/A	$0.25 per share	6.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GGD GoGold Resources	C$1.63M	C$0.01	223.76	∞	N/A	4.64%	0.60%	0.04%	N/A
ITR Integra Resources	-C$40.04M	-C$0.48	N/A	∞	N/A	N/A	-63.49%	-17.95%	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	-$1.68M	$0.35	22.17	77.60	N/A	3.67%	-0.47%	-0.38%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	N/A

Latest ITR, SLS, NSR, and GGD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GGD GoGold Resources	N/A	N/A	N/A	N/A	N/A
ITR Integra Resources	N/A	N/A	N/A	N/A	N/A
NSR Neustar, Inc. Neustar, Inc. Cla	$0.16	2.06%	N/A	45.71%	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GGD GoGold Resources	N/A	6.95	8.30
ITR Integra Resources	35.54	0.82	1.49
NSR Neustar, Inc. Neustar, Inc. Cla	0.13	1.73	1.73
SLS SELLAS Life Sciences Group	N/A	4.91	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GGD GoGold Resources	28.90%
ITR Integra Resources	26.52%
NSR Neustar, Inc. Neustar, Inc. Cla	1.49%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
GGD GoGold Resources	6.41%
ITR Integra Resources	17.78%
NSR Neustar, Inc. Neustar, Inc. Cla	N/A
SLS SELLAS Life Sciences Group	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GGD GoGold Resources	204	232.69 million	N/A	Not Optionable
ITR Integra Resources	41	118.19 million	N/A	Not Optionable
NSR Neustar, Inc. Neustar, Inc. Cla	N/A	61.59 million	N/A	Not Optionable
SLS SELLAS Life Sciences Group	10	105.30 million	98.38 million	Not Optionable

ITR, SLS, NSR, and GGD Headlines

Recent News About These Companies

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Earnings Results

August 14 at 6:29 PM | marketbeat.com

Sellas Life Sciences Reports Q2 2025 Financial Results

August 13 at 5:23 AM | msn.com

Sellas Life Sciences reports Q2 EPS (7c), consensus (8c)

August 12 at 12:22 AM | msn.com

SELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 12 at 7:21 PM | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...

August 9, 2025 | finance.yahoo.com

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

August 7, 2025 | globenewswire.com

SELLAS Life Sciences Group (SLS) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

July 31, 2025 | zacks.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 1.8% - What's Next?

July 31, 2025 | marketbeat.com

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

July 30, 2025 | marketbeat.com

SELLAS Life Sciences Group (NASDAQ:SLS) Price Target Raised to $7.00

July 16, 2025 | marketbeat.com

Sellas Flat on Trial Success

July 16, 2025 | baystreet.ca

SELLAS gains as mid-stage trial for leukemia drug succeeds

July 16, 2025 | msn.com

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ITR, SLS, NSR, and GGD Company Descriptions

GoGold Resources TSE:GGD

C$2.23 -0.06 (-2.62%)

As of 08/14/2025 04:00 PM Eastern

GoGold Resources Inc is a Canadian-based company engaged in the business of exploration, development, and production of gold and silver. It operates in two segments: Mexico, which accounts for the majority of revenue; and Canada. Its Mexico segment consists of the Parral project and the Los Ricos project.

Integra Resources CVE:ITR

C$2.30 -0.02 (-0.86%)

As of 08/14/2025 04:00 PM Eastern

Integra Resources Corp., a precious metals exploration and development company, engages in the acquisition, exploration, and development of mineral properties in the Great Basin of the Western United States. The company explores for gold and silver deposits. It primarily focuses on developing DeLamar Project located in southwestern Idaho; and the Wildcat and Mountain View Projects located in western Nevada. It also holds a portfolio of early-stage exploration projects in Idaho, Nevada, and Arizona. The company was formerly known as Mag Copper Limited and changed its name to Integra Resources Corp. in August 2017. Integra Resources Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Neustar, Inc. Neustar, Inc. Cla NYSE:NSR

NeuStar, Inc. is a global information services provider. The Company's cloud-based platforms and differentiated data sets offer informative, real-time analytics, which enable clients to make actionable, data-driven decisions. It provides chief marketing officers a suite of services to plan their media spends, identify and locate desired customers, invest in marketing campaigns, deliver relevant offers and measure the performance of these activities. Security professionals use the Company's solutions to maximize Web performance and protect against malicious attacks. It enables the exchange of essential operating information across multiple carriers to provision and manage services, assisting clients with order processing and routing of customer inquiries. The Company's services include marketing services, security services, data services and number portability administration center (NPAC) services.

SELLAS Life Sciences Group NASDAQ:SLS

$1.55 0.00 (0.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.01 (+0.65%)

As of 08/14/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time